Drug Profile
ASP 7991
Alternative Names: ASP7991Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class
- Mechanism of Action Calcium-sensing receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Secondary hyperparathyroidism
Most Recent Events
- 31 May 2015 Discontinued - Phase-II for Secondary hyperparathyroidism in Japan (PO)
- 01 Nov 2014 Astellas Pharma completes a phase II trial for Secondary hyperparathyroidism in Japan (NCT02133404)
- 03 Feb 2014 Phase-II clinical trials in Secondary hyperparathyroidism in Japan (PO)